Menu Back toSession-3-Value-to-Patients

Biosimilars Conference

Session 6: What’s the Value to Patients and What Challenges Exist to Access?

Session Chair(s)

Mary Jo  Carden, JD, RPh

Mary Jo Carden, JD, RPh

  • Head, Policy
  • Sandoz, Inc., United States

Biosimilars offer safe, effective, and more affordable alternatives to patients who use biologic medications for managing chronic conditions. To date, biosimilars have not necessarily achieved the expected goals of allowing patients to have access to more affordable biologic medications. This session will enable participates to hear the patient perspective on biosimilars and recommendations for overcoming current challenges and barriers. Issues considered will include potential cost savings of biosimilars to patients and the health care system, the implications of how access to biosimilars may improve adherence to biologics, and ways that savings from biosimilars may improve patient care through better access to services and patient support.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the current environment in the United States related to patient access to biosimilars
  • Identify challenges in patient access to biosimilars including regulatory issues, payment issues, and education
  • Describe 1-2 ways that current challenges may be improved


Benjamin  Chandhok

Implications to Biosimilar Access for Patients with Arthritis

Benjamin Chandhok

  • Senior Director, State Legislative Affairs
  • Arthritis Foundation, United States
Laura  Lasiter

How Can Biosimilars Benefit Patients with Cancer and What Are Challenges to Access?

Laura Lasiter

  • Science Policy Analyst
  • Friends of Cancer Research, United States

Contact us

Registration Questions?

Send Email

Check out our 2019 Program!